Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 1;38(22):4384–4396. doi: 10.1038/s41388-019-0729-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Targeting of NFATc2 in melanoma cells downregulates c-Myc, FOXM1, and EZH2. a Expression by western blotting of NFATc2, c-Myc, FOXM1, EZH2, and H3K27me3 in three melanoma cell lines (Me71, Me79, Me98) at 72 h after transfection with two different NFATc2-specific Stealth siRNA (NFATc2 siRNA-1 and siRNA-2) or with control siRNA (ctrl siRNA). b, c Expression of NFATc2, c-Myc, FOXM1, EZH2, and H3K27me3 in b NFATc2 shRNA stable transfectants (NFATc2 shRNA_86a, and NFATc2 shRNA_87a) or in control cells (ctrl shRNA), or c in melanoma cell lines Me71, Me79, and Me98 treated or not for 144 h with the NFATc2 inhibitor AM404 (at 20 μM)